基于静态头空间采样和GC-ECD,分析Febuxostat中的基化物基因毒性杂质
Alexandros Kavrentzos1,2, Elli Vastardi2, Evangelos Karavas2
1Laboratory of Pharmaceutical Analysis, Department of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Pharmaceuticals (Basel, Switzerland)
|April 27, 2024
概括
一种新的气相色谱电子捕获探测器 (GC-ECD) 方法准确量化了Febuxostat活性药物成分 (API) 中的五种基因毒性杂质. 这种经过验证的方法通过检测微量杂质水平来确保药物安全.
科学领域:
- 分析化学 分析化学
- 药品分析 药品分析
背景情况:
- 基因毒性杂质在制药产品中构成重大风险.
- 治疗痛风的药物Febuxostat需要严格的质量控制,以确保患者的安全.
- 检测特定杂质的微量含量对于制药API质量至关重要.
研究的目的:
- 开发和验证一种敏感和选择性的分析方法,用于量化Febuxostat API中的五种含的基因毒性杂质.
- 为了优化头部空间采样 (HS) 参数,以便有效地提取杂质.
- 确保该方法符合制药分析的监管标准 (ICH指南).
主要方法:
- 用电子捕获探测器 (GC-ECD) 结合头部空间采样 (HS) 的气相色谱.
- 多变量实验设计 (分数因数设计和中央复合设计) 用于优化HS参数.
- 根据ICH指南验证方法,包括特异性,线性,LOD,LOQ,精度和准确性.
主要成果:
- 优化HS条件:5分钟的提取时间和120°C的提取温度.
- 在0.003-0.009μg mL−1之间达到检测极限 (LOD),在0.01-0.03μg mL−1.1之间达到量化极限 (LOQ).
- 该方法表现出高精度 (81.5-118.2%的恢复) 和精度 (<9.9%的RSD).
结论:
- 一种使用HS的经过验证,敏感和选择性的GC-ECD方法已成功开发,用于在Febuxostat API中确定微量基因毒性杂质.
- 优化的方法可提供关键杂质的可靠量化,支持Febuxostat API质量控制.
- 经过验证的分析协议适用于Febuxostat API批次的常规分析.
更多相关视频
相关概念视频
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...